Skip to main content
SpringerLink
Log in

Molecular Obesity, Potency and Other Addictions in Drug Discovery

  • Conference paper
  • First Online:
Multifaceted Roles of Crystallography in Modern Drug Discovery

Abstract

Achieving the right balance of properties in a candidate drug molecule is a very complex challenge as many of them are in conflict with each other. Structure Based Drug Design is a key tool in the medicinal chemists toolkit but can lead to an over dependence on potency if not used in conjunction with physical chemistry predictions and measurements to maintain the property balance needed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hann MM (2011) Molecular obesity, potency and other addictions in medicinal chemistry. Med Chem Commun 2:349–355

    Article  CAS  Google Scholar 

  2. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–716

    Article  CAS  PubMed  Google Scholar 

  3. Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6:881–890

    Article  CAS  PubMed  Google Scholar 

  4. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3–26

    Article  Google Scholar 

  5. Hughes JD et al (2008) Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 18:4872–4875

    Article  CAS  PubMed  Google Scholar 

  6. Gleeson MP (2008) Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 51:817–834

    Article  CAS  PubMed  Google Scholar 

  7. Ritchie TJ, Macdonald SJ (2009) The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design? Drug Discov Today 14:1011–1020

    Article  CAS  PubMed  Google Scholar 

  8. Young RJ, Green DVS, Luscombe CN, Hill AP (2011) Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. Drug Discov Today 16:822–830

    Article  CAS  PubMed  Google Scholar 

  9. Lovering F, Bikker J, Humblet C (2009) Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem 52:6752–6756

    Article  CAS  PubMed  Google Scholar 

  10. Hann MM, Leach AR, Harper G (2001) Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 41(3):856–864

    Article  CAS  PubMed  Google Scholar 

  11. Waring MJ (2009) Defining optimum lipophilicity and molecular weight ranges for drug candidates – molecular weight dependent lower log D limits based on permeability. Bioorg Med Chem Lett 19:2844–2851

    Article  CAS  PubMed  Google Scholar 

  12. Hopkins AL, Groom CR, Alex A (2004) Ligand efficiency: a useful metric for lead selection. Drug Discov Today 9:430–431

    Article  PubMed  Google Scholar 

  13. Mortenson PN, Murray CW (2011) Assessing the lipophilicity of fragments and early hits. J Comput Aided Mol Des 25:663–667

    Article  CAS  PubMed  Google Scholar 

  14. Hopkins AL, Mason JS, Overington JP (2006) Can we rationally design promiscuous drugs? Curr Opin Struct Biol 16:127–137

    Article  CAS  PubMed  Google Scholar 

  15. Leach AR, Hann MM (2011) Molecular complexity and fragment-based drug discovery: ten years on. Curr Opin Chem Biol 15:489–496

    Article  CAS  PubMed  Google Scholar 

  16. Hann MM, Leach AR. Coping with complexity in molecular design. In: De novo molecular design. Wiley-VCH, Weinheim. ISBN 978-3-527-33461-2

    Google Scholar 

  17. Olsson TS, Williams MA, Pitt WR, Ladbury JE (2008) The thermodynamics of protein-ligand interaction and solvation: insights for ligand design. J Mol Biol 384:1002–1017

    Article  CAS  PubMed  Google Scholar 

  18. (A) Ferenczy GG, Keserű GM (2010) Thermodynamics guided lead discovery and optimization. Drug Discov Today 15:919. (B) Ferenczy GG, Keserű GM (2010) Enthalpic efficiency of ligand binding. J Chem Inf Model 50:1536

    Google Scholar 

  19. Hann MM, Keserű GM (2012) Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat Rev Drug Discov 11:355–365

    Article  CAS  PubMed  Google Scholar 

  20. Selzer P, Roth HJ, Ertl P, Schuffenhauer A (2005) Complex molecules: do they add value? Curr Opin Chem Biol 9:310–316

    Article  CAS  PubMed  Google Scholar 

  21. Bajorath J (2002) Integration of virtual and high-throughput screening. Nat Rev Drug Discov 1:882–894

    Article  CAS  PubMed  Google Scholar 

  22. Nadin A, Hattotuwagama C, Churcher I (2012) Lead-oriented synthesis: a new opportunity for synthetic chemistry. Angew Chem Int Ed 51:1114–1122

    Article  CAS  Google Scholar 

  23. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5:993–996

    Article  CAS  PubMed  Google Scholar 

  24. Perola E (2010) An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. J Med Chem 53:2986–2997

    Article  CAS  PubMed  Google Scholar 

  25. Braggio S, Montanari D, Rossi T, Ratti E (2010) Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates. Expert Opin Drug Discov 5:609–618

    Article  CAS  PubMed  Google Scholar 

  26. Montanari D et al (2011) Application of drug efficiency index in drug discovery. Expert Opin Drug Discov 6:913–920

    Article  CAS  PubMed  Google Scholar 

  27. Wager TT et al (2013) Improving the odds of success in drug discovery: choosing the best compounds for in vivo toxicology studies. J Med Chem 56:9771–9779

    Article  CAS  PubMed  Google Scholar 

  28. Uetrecht J (2007) Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 47:513–539

    Article  CAS  PubMed  Google Scholar 

  29. Mateus A, Matsson P, Artursson P (2013) Rapid measurements of intracellular unbound drug concentrations. Mol Pharm 10:2467–2478

    Article  CAS  PubMed  Google Scholar 

  30. Waring MJ (2010) Lipophilicity in drug discovery. Expert Opin Drug Discov 5(3):235–248

    Article  CAS  PubMed  Google Scholar 

  31. Leeson PD, Empfield JR (2010) Reducing the risk of drug attrition associated with physicochemical properties. Annu Rep Med Chem 45:393–407

    Article  CAS  Google Scholar 

  32. Gleeson MP, Hersey A, Montanari D, Overington J (2011) Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov 10:197–208

    Article  CAS  PubMed  Google Scholar 

  33. Hopkins AL et al (2014) The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov 13:105–121

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. GlaxoSmithKline Research and Development, Chemical Sciences, Molecular Discovery Research, Gunnels Wood Rd., Stevenage, SG1 2NY, UK

    Michael M. Hann

Authors
  1. Michael M. Hann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael M. Hann .

Editor information

Editors and Affiliations

  1. Structural Chemistry Department, Merck & Co, Inc., Kenilworth, New Jersey, USA

    Giovanna Scapin

  2. Center for Advanced Biotechnology and Medicine, and Rutgers University, Piscataway, New Jersey, USA

    Disha Patel

  3. Center for Advanced Biotechnology and Medicine, and Rutgers University, Piscataway, New Jersey, USA

    Eddy Arnold

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media Dordrecht

About this paper

Cite this paper

Hann, M.M. (2015). Molecular Obesity, Potency and Other Addictions in Drug Discovery. In: Scapin, G., Patel, D., Arnold, E. (eds) Multifaceted Roles of Crystallography in Modern Drug Discovery. NATO Science for Peace and Security Series A: Chemistry and Biology. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-9719-1_14

Download citation

Publish with us

Policies and ethics

Search

Navigation